5 most widely read First Opinions of 2019 – STAT

Michelle C. Werner agonized over whether the gene therapy treatment Elevidys was right for her teenage son. But to him, the answer was obvious.

Published in BMJ Open Sport and Exercise, the study looked at athletes with spinal cord injuries to better understand neuropathic pain.

Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech.

The overlapping symptoms of long Covid and persistent Lyme challenge patients and doctors alike. Researchers are seeking biomarkers and devising “cross-illness” trials.

Blood tests set to norms based on the physiology of white men can lead to misdiagnosis and unnecessary health scares for people of different races.

Pediatric cancer treatments have been neglected. Two U.K. charities are starting a consortium to advance new molecules to a “drug candidate” stage, for handoff to…

Could raw milk — or a cat — help explain how a person who had no contact with animals caught H5 bird flu?

The insurer UnitedHealth is using its unrivaled physician empire to enrich itself by milking Medicare Advantage.

In a first, a new heart disease risk calculator uses social factors to try to make predictions more accurate.

A CRISPR-augmented stem cell transplant has shown preliminary evidence that it can delay relapse in some cancer patients.